Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Absorption and Excretion of Docetaxel (as ModraDoc 006 Tablets) After Oral Administration in Combination With Ritonavir

NCT05242926 is registered in ClinicalTrials.gov with Modra Pharmaceuticals as lead sponsor.

NCT NCT05242926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05242926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Absorption and Excretion of Docetaxel (as ModraDoc 006 Tablets) After Oral Administration in Combination With Ritonavir
Lead sponsor
Modra Pharmaceuticals
Phase
Phase 1
Overall status
Withdrawn
Start date
October 31, 2017
Completion date
June 30, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult